Atossa Q1 2023: cash $103.9M, no debt; Phase 2 trials initiated/expanded

ATOSSA THERAPEUTICS, INC.

2024-Q1 EPS reported -$0.05

Ended Q1 2023 with $103.9M cash and cash equivalents, zero debt.
Operating expenses $7.1M (up 50% YoY); R&D $3.5M (+134%) on (Z)-endoxifen trials.
Initiated Phase 2 EVANGELINE and new I-SPY 2 arm for (Z)-endoxifen in ER+/HER2- breast cancer.
Full enrollment of Phase 2 KARISMA breast density study expected by end of 2023.
US patent granted for (Z)-endoxifen enteric capsule (No. 11,572,334).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2023.

Period: fiscal quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments.

View on SEC.gov

Browse all earnings releases →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-014365

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.